You have read all your free articles, to continue reading subscribe to read the rest of this content.
Xbrane Biopharma has announced results from the six months interim read-out in the Phase III equivalence trial with the Lucentis biosimilar candidate Xlucane. Xlucane met the primary endpoint demonstrating equivalent efficacy in change of BCVA (Best Corrected Visual Acuity) at week 8 of treatmentAlready a subscriber Login You have read…
New research shows that ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including Amyothrophic Lateral Sclerosis (ALS). TikoMed has announced the publication in Frontiers in Phamacology of peeAlready a subscriber Login You have read all your free articles,…
Nordic Nanovector will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment. This decision has been made based on the company’s reviewed discussions with the US Food aAlready a…
Ultimovacs has announced continuing positive efficacy data in its ongoing US-based phase I clinical trial, UV1-103. The study evaluates the company's universal cancer vaccine, UV1, in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, as first-line treatment in advanced non-resectAlready a subscriber Login You have read all your free articles, to…
